Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnolia: Abelacimab versus dalteparin in cancer-associated venous thromboembolism
CTR20232552Phase 3Terminated
- Sponsor
- Anthos Therapeutics
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of abelacimab in venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE), sponsored by Anthos Therapeutics. Started Aug 2023; status: terminated.
02
Drugs
abelacimab
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on CTR20232552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232552.